Biomarkers Market Growth, Drivers, and Opportunities

Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

USD 104.15 BN

MARKET SIZE, 2030

CAGR 10.8%

(2025-2030)

557

REPORT PAGES

704

MARKET TABLES

OVERVIEW

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The biomarkers market is projected to reach USD 104.15 billion by 2030 from USD 62.39 billion in 2025 at a CAGR of 10.8% from 2025 to 2030. The market growth is fueled by the increasing use of biomarkers in drug discovery, which helps identify disease mechanisms and enhances the accuracy of clinical trials.

KEY TAKEAWAYS

BY REGION

The North America biomarkers market dominated, with a share of 40.2% in 2024. The large share of North America can be attributed to the presence of key biopharmaceutical research and development facilities and the rising number of drug development projects.
BY OFFERING

By offering, the consumables segment is expected to dominate the market, growing at the highest CAGR of 11.5%. The growth in this segment is driven by the necessity for high-quality products to ensure accurate test results in research and clinical settings.
BY TYPE

By type, the safety biomarkers segment accounted for the largest share of 48.1%. market. The large share of this segment is due to its essential role in ensuring the safety and effectiveness of pharmaceuticals and healthcare interventions.
BY RESEARCH AREA

By research area, the genomics segment is expected to register the highest CAGR of 11.6%. Increasing advancements in genomics technologies for biomarker testing are expected to drive the growth in this segment.
COMPETITIVE LANDSCAPE

F. Hoffmann-La Roche Ltd, Merck KGaA, Abbott, Thermo Fisher Scientific Inc. and QIAGEN were identified as Star players in the biomarkers market, as they have focused on innovation and have broad industry coverage and strong operational & financial strength.

The biomarkers market is projected to grow significantly over the next decade, driven by the increasing use of biomarkers in drug discovery, which helps identify disease mechanisms and enhances the accuracy of clinical trials. Investments in omics technologies, including genomics, proteomics, and transcriptomics, are improving the processes for biomarker identification and validation. Moreover, both governments and private organizations are providing more funding and grants for biomarker research.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The biomarkers market is witnessing a major transformation driven by new technologies, evolving applications, and strategic collaborations. The revenue mix is expected to shift significantly as companies move from conventional models toward multi-omics integration, AI-enabled biomarker discovery, and liquid biopsy innovations. Pharmaceutical and biotechnology companies, hospitals, academic institutions, and other end users are prioritizing assay validation, regulatory compliance, and precision diagnostics. These advancements aim to accelerate disease detection, improve patient stratification, reduce clinical trial failures, and enhance precision medicine outcomes, ultimately driving better healthcare efficiency and early diagnosis worldwide.

biomarkers-advanced-technologies-and-global-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers

Impact
Level

Increasing use of biomarkers in drug discovery & development
Growing importance of companion diagnostics

RESTRAINTS

Impact
Level

High capital investments and extensive timelines for biomarker development
Disease complexity and heterogeneity

OPPORTUNITIES

Impact
Level

Growing preference for personalized medicine and precision oncology
High growth potential of emerging economies

CHALLENGES

Impact
Level

Issues associated with quantification & validation of biomarkers
Complexities associated with data set integration

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing use of biomarkers in drug discovery & development

The growing use of biomarkers in drug discovery and development enhances disease understanding, patient selection, and therapeutic efficacy. Their integration accelerates clinical trials, reduces costs, and improves success rates by enabling more targeted, data-driven drug development strategies across pharmaceutical and biotechnology research programs.

Restraint: High capital investments and extensive timelines for biomarker development

Developing reliable biomarkers requires substantial investment, advanced infrastructure, and long validation timelines. High R&D costs, regulatory complexities, and limited funding restrict smaller players, slowing innovation and commercial adoption. These factors collectively hinder the large-scale implementation of biomarkers in clinical and research applications

Opportunity: Growing preference for personalized medicine and precision oncology

The rising focus on personalized medicine and precision oncology offers strong growth prospects for the biomarkers market. Biomarkers are vital for identifying patient-specific traits, predicting drug response, and monitoring therapy effectiveness, driving their adoption in companion diagnostics and targeted treatment development.

Challenge: Issues associated with quantification & validation of biomarkers

Accurate quantification and validation remain key challenges in biomarker research. Variations in assay performance, lack of standardization, and reproducibility issues impede clinical translation and regulatory approval. Addressing these limitations is crucial to ensure data reliability and accelerate biomarker integration into diagnostic and therapeutic applications.

biomarkers-advanced-technologies-and-global-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Collaborated with the COPD Foundation Biomarker Qualification Consortium, developed and validated plasma fibrinogen as a prognostic biomarker for chronic obstructive pulmonary disease (COPD)	Enabled selection of high-risk patients, reduced trial size and duration, and improved statistical power and regulatory acceptance for biomarker-driven studies
	Applied bioinformatics to identify KRAS pathway biomarkers that rescued a failing oncology clinical trial by defining a responder subgroup	Enabled redesign of the trial with biomarker-guided patient selection, demonstrated efficacy in a specific subgroup, and revived a previously non-performing drug candidate

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The biomarkers market ecosystem comprises raw material suppliers (Biosynth, Creative Diagnostics), product manufacturers (Agilent Technologies, Thermo Fisher Scientific), service providers (JSR Corporation, Eurofins), and end users (Novartis,Massachusetts General Hospital). Raw materials like reagents, assay kits, antibodies, and detection enzymes are utilized to develop, validate, and apply biomarkers in disease diagnosis, drug discovery, and clinical research. Product manufacturers ensure standardized assay platforms and analytical instruments, while service providers deliver biomarker validation, testing, and translational research support. End users drive demand for accuracy, clinical relevance, and regulatory compliance, fostering collaboration across the value chain. This integrated ecosystem promotes innovation in precision medicine, early disease detection, and personalized therapeutic development.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Biomarkers Market, By Offering

In 2024, the consumables segment accounted for the largest share of the biomarkers market. The high demand for consumables stems from the necessity for high-quality products to ensure accurate and reliable results in biomarker testing.

Biomarkers Market, By Type

In 2024, the safety biomarkers segment accounted for the largest share of the biomarkers market. The large share of this segment is due to its essential role in ensuring the safety and effectiveness of pharmaceuticals and healthcare interventions.

Biomarkers Market, By Application

In 2024, the clinical diagnostics segment accounted for the largest share of the biomarkers market. The large share of this segment can be attributed to the increasing use of biomarkers for disease diagnosis and the rising incidence of chronic diseases such as cancer, infectious diseases, cardiovascular disorders, and neurological disorders.

REGION

Asia Pacific to be fastest-growing region in global biomarkers market during forecast period

The Asia Pacific biomarkers market is expected to register the highest CAGR during the forecast period, primarily due to the rising incidence of chronic diseases, the rapid expansion of drug discovery & development projects, increasing R&D spending on biopharmaceutical projects, and the growth of the biotechnology industry in emerging economies.

biomarkers-advanced-technologies-and-global-market Region

biomarkers-advanced-technologies-and-global-market: COMPANY EVALUATION MATRIX

F. Hoffmann-La Roche Ltd (Star) leads the biomarkers market with a strong global footprint, leveraging its extensive portfolio of biomarker-based diagnostics, companion diagnostics, and precision medicine platforms integrated across its pharmaceutical and diagnostics divisions. The company’s regulatory expertise, clinical validation capabilities, and strategic collaborations reinforce its leadership in biomarker innovation across oncology, neurology, and infectious diseases. Guardant Health (Emerging Leader) is rapidly strengthening its market position through advanced liquid biopsy and genomic profiling technologies, addressing the growing demand for non-invasive, real-time, and clinically actionable biomarker testing solutions.

biomarkers-advanced-technologies-and-global-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

F.Hoffmann-La Roche Ltd (Switzerland)
Merck KGaA (Germany)
Thermo Fisher Scientific Inc. (US)
Abbott (US)
QIAGEN (Germany)
Revvity (US)
Charles River Laboratories (US)
Eurofins Scientific (Luxembourg)
BioMérieux (France)
Agilent Technologies, Inc. (US)
Guardant Health (US)
Bio-Rad Laboratories (US)
Illumina, Inc. (US)

MARKET SCOPE

REPORT METRIC	DETAILS
Market Size in 2024 (Value)	USD 58.07 Billion
Market Forecast in 2030 (Value)	USD 104.15 Billion
Growth Rate	CAGR of 10.8% from 2025 to 2030
Years Considered	2023–2030
Base Year	2024
Forecast Period	2025–2030
Units Considered	Value (USD Billion)
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Offering: Consumables Services Software By Type: Safety Biomarkers Efficacy Biomarkers Validation Biomarkers By Research Area: Genomics Proteomics Metabolomics Other Research Areas By Technology: Immunoassays Next-generation Sequencing Polymerase Chain Reaction Mass Spectrometry Chromatography Other Technologies By Disease Indication: Cancer Infectious Diseases Neurological Diseases Cardiovascular Diseases Other Disease Indications By Application: Clinical Diagnostics Drug Discovery & Development Personalized Medicine Clinical Research Other Applications By End User: Pharmaceutical & Biotechnology Companies Hospitals & Diagnostic Laboratories Academic & Research Institutes Other End Users
Regions Covered	North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: biomarkers-advanced-technologies-and-global-market REPORT CONTENT GUIDE

biomarkers-advanced-technologies-and-global-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST	CUSTOMIZATION DELIVERED	VALUE ADDS
Rest of Asia Pacific Breakdown	Country-level market sizing and growth forecasts (Taiwan, North Korea, New Zealand, Vietnam, the Philippines, Singapore, Malaysia,Thailand, Indonesia, and other Asia Pacific countries)	Provides granular country-level insights, enabling clients to prioritize high-growth markets, and tailor portfolio strategies
Company Evaluation	Detailed analysis and profiling of top five market players Portfolio assessment of top five companies	Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions

RECENT DEVELOPMENTS

May 2025 : Roche introduced the Elecsys PRO-C3 test, a biomarker-based diagnostic tool, developed with Nordic Bioscience to evaluate liver fibrosis severity in patients with MASLD (metabolic dysfunction-associated steatotic liver disease).
April 2025 : Eurofins Scientific acquired SYNLAB's clinical diagnostics operations in Spain, which include genetics and anatomical pathology services. These services complement Eurofins' existing clinical diagnostics capabilities and significantly expand its reach in the Spanish market. The acquisition supports Eurofins' biomarker services by strengthening its access to patient samples, enhancing laboratory throughput, and expanding its capabilities in molecular diagnostics, essential for biomarker discovery, validation, and clinical application.
January 2025 : Merck established a multi-year partnership with Opentrons Labworks to automate its biology assay kits using the Opentrons Flex robotic workstation. This collaboration aims to enhance workflows related to protein sample preparation, molecular assays, and cell-based research, which are crucial for biomarker discovery and validation.
January 2025 : Thermo Fisher Scientific teamed up with the UK Biobank Pharma Proteomics Project (UKB-PPP) to conduct the world's largest proteomics study focused on biomarkers. Utilizing Thermo Fisher's Olink Explore Platform, this collaboration will analyze more than 5,400 proteins from 600,000 human samples, aiming to accelerate the discovery of protein biomarkers associated with various diseases.

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE

PAGE NO

INTRODUCTION

RESEARCH METHODOLOGY

EXECUTIVE SUMMARY

PREMIUM INSIGHTS

MARKET OVERVIEW

Biomarker advancements drive precision medicine amid investment challenges and regulatory complexities.

5.1

INTRODUCTION

5.2

MARKET DYNAMICS

5.2.1

MARKET DRIVERS

5.2.1.1

INCREASING USE OF BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT

5.2.1.2

GROWING IMPORTANCE OF COMPANION DIAGNOSTICS

5.2.1.3

RISING PREVALENCE OF CANCER

5.2.1.4

DEVELOPMENT OF BIOMARKERS FOR RARE DISEASES

5.2.1.5

INCREASING FUNDS AND GRANTS FOR BIOMARKER RESEARCH

5.2.1.6

ADVANCEMENT IN OMICS TECHNOLOGIES

5.2.2

RESTRAINTS

5.2.2.1

HIGH CAPITAL INVESTMENTS AND EXTENSIVE TIMELINES FOR BIOMARKER DEVELOPMENT

5.2.2.2

DISEASE COMPLEXITY AND HETEROGENEITY

5.2.3

OPPORTUNITIES

5.2.3.1

GROWING PREFERENCE FOR PERSONALIZED MEDICINE AND PRECISION ONCOLOGY

5.2.3.2

ENHANCED COLLABORATION AMONG HEALTHCARE PROVIDERS AND KEY INDUSTRY PLAYERS

5.2.3.3

HIGH GROWTH POTENTIAL OF EMERGING ECONOMIES

5.2.4

CHALLENGES

5.2.4.1

ISSUES ASSOCIATED WITH QUANTIFICATION & VALIDATION OF BIOMARKERS

5.2.4.2

COMPLEXITIES ASSOCIATED WITH DATA SET INTEGRATION

5.2.4.3

TECHNICAL ISSUES RELATED TO SAMPLE COLLECTION AND STORAGE

5.3

TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

5.4

REGULATORY ANALYSIS

5.4.1

REGULATORY SCENARIO

5.4.1.1

5.4.1.2

EUROPE

5.4.1.3

ASIA PACIFIC

5.4.1.4

REST OF THE WORLD

5.4.2

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.5

VALUE CHAIN ANALYSIS

5.6

TECHNOLOGICAL ANALYSIS

5.6.1

KEY TECHNOLOGIES

5.6.1.1

IMMUNOASSAYS

5.6.1.2

NEXT-GENERATION SEQUENCING (NGS)

5.6.1.3

POLYMERASE CHAIN REACTION (PCR)

5.6.1.4

IN SITU HYBRIDIZATION

5.6.1.5

MICROARRAYS

5.6.1.6

MASS SPECTROMETRY

5.6.2

COMPLEMENTARY TECHNOLOGIES

5.6.2.1

LIQUID BIOPSY

5.6.2.2

CRISPR

5.6.3

ADJACENT TECHNOLOGIES

5.6.3.1

ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML)

5.6.3.2

SENSORS (WEARABLE DEVICES)

5.7

PRICING ANALYSIS

5.7.1

INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022–2024

5.7.2

INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024

5.8

PATENT ANALYSIS

5.8.1

METHODOLOGY

5.8.2

NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2025

5.9

ECOSYSTEM ANALYSIS

5.10

KEY CONFERENCES & EVENTS, 2025–2026

5.11

PORTER’S FIVE FORCES ANALYSIS

5.11.1

INTENSITY OF COMPETITIVE RIVALRY

5.11.2

BARGAINING POWER OF SUPPLIERS

5.11.3

BARGAINING POWER OF BUYERS

5.11.4

THREAT OF SUBSTITUTES

5.11.5

THREAT OF NEW ENTRANTS

5.12

KEY STAKEHOLDERS & BUYING CRITERIA

5.12.1

KEY STAKEHOLDERS IN BUYING PROCESS

5.12.2

BIOMARKERS MARKET: BUYING CRITERIA

5.13

INVESTMENT & FUNDING SCENARIO

5.14

TRADE DATA ANALYSIS

5.14.1

IMPORT SCENARIO: HS CODE 382200, 2020–2024

5.14.2

EXPORT SCENARIO: HS CODE 382200, 2020–2024

5.15

IMPACT OF AI/GENERATIVE AI ON BIOMARKERS MARKET

5.15.1

INTRODUCTION

5.15.2

USE CASES

5.15.3

FUTURE OF AI IN BIOMARKER ECOSYSTEM

5.16

IMPACT OF 2025 US TARIFF ON BIOMARKERS MARKET

5.16.1

KEY TARIFF RATES

5.16.2

PRICE IMPACT ANALYSIS

5.16.3

IMPACT ON COUNTRIES/REGIONS

5.16.3.1

5.16.3.2

EUROPE

5.16.3.3

ASIA PACIFIC

5.16.4

IMPACT ON END-USE INDUSTRIES

5.16.4.1

PHARMACEUTICAL & BIOTECH COMPANIES

5.16.4.2

HOSPITALS & DIAGNOSTIC LABORATORIES

5.16.4.3

CONTRACT RESEARCH ORGANIZATIONS

BIOMARKERS MARKET, BY OFFERING

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 44 Data Tables

123

6.1

INTRODUCTION

6.2

CONSUMABLES

6.2.1

ASSAY KITS

6.2.1.1

GROWING DEMAND FOR ASSAY KITS IN BIOMARKER DETECTION, QUANTIFICATION, AND CHARACTERIZATION TO SUPPORT GROWTH

6.2.2

REAGENTS & CHEMICALS

6.2.2.1

RECURRENT USAGE OF REAGENTS & CHEMICALS IN DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT DEMAND

6.2.3

OTHER CONSUMABLES

6.3

SERVICES

6.3.1

GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION

6.4

SOFTWARE

6.4.1

INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH

BIOMARKERS MARKET, BY TYPE

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 51 Data Tables

147

7.1

INTRODUCTION

7.2

SAFETY BIOMARKERS

7.2.1

WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS TO BOOST MARKET GROWTH

7.3

EFFICACY BIOMARKERS

7.3.1

PREDICTIVE BIOMARKERS

7.3.1.1

RISING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE TO DRIVE MARKET

7.3.2

SURROGATE BIOMARKERS

7.3.2.1

ABILITY TO SERVE AS RELIABLE INDICATOR IN PLACE OF CLINICAL ENDPOINTS TO SUPPORT MARKET GROWTH

7.3.3

PHARMACODYNAMIC BIOMARKERS

7.3.3.1

INCREASING UTILIZATION OF PHARMACODYNAMIC BIOMARKERS IN BIOMARKER AND DRUG DEVELOPMENT TO BOOST MARKET

7.3.4

PROGNOSTIC BIOMARKERS

7.3.4.1

INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT GROWTH OF PROGNOSTIC BIOMARKERS

7.4

VALIDATION BIOMARKERS

7.4.1

RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH

BIOMARKERS MARKET, BY RESEARCH AREA

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 29 Data Tables

174

8.1

INTRODUCTION

8.2

GENOMICS

8.2.1

ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH

8.3

PROTEOMICS

8.3.1

GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND

8.4

METABOLOMICS

8.4.1

RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH

8.5

OTHER RESEARCH AREAS

BIOMARKERS MARKET, BY TECHNOLOGY

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 65 Data Tables

190

9.1

INTRODUCTION

9.2

IMMUNOASSAYS

9.2.1

ELISA

9.2.1.1

EXTENSIVE APPLICATION OF ELISA ASSAYS IN CLINICAL LABORATORIES TO SUPPORT GROWTH

9.2.2

PROTEIN MICROARRAYS

9.2.2.1

QUICK AND COST-EFFECTIVE NATURE OF TECHNOLOGY TO SUPPORT GROWTH

9.2.3

WESTERN BLOT

9.2.3.1

INCREASING INVESTMENTS IN PROTEOMICS RESEARCH TO DRIVE MARKET

9.3

NEXT-GENERATION SEQUENCING (NGS)

9.3.1

TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH

9.4

POLYMERASE CHAIN REACTION (PCR)

9.4.1

RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET

9.5

MASS SPECTROMETRY

9.5.1

INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH

9.6

CHROMATOGRAPHY

9.6.1

GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH

9.7

OTHER TECHNOLOGIES

BIOMARKERS MARKET, BY DISEASE INDICATION

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 47 Data Tables

225

10.1

INTRODUCTION

10.2

CANCER

10.2.1

INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH AND DIAGNOSIS TO DRIVE MARKET

10.3

INFECTIOUS DISEASES

10.3.1

INCREASING RESEARCH AND GROWING FUNDING TO IDENTIFY BIOMARKERS FOR INFECTIOUS DISEASES TO DRIVE DEMAND

10.4

IMMUNOLOGICAL DISORDERS

10.4.1

RISING ADOPTION OF ASSAYS FOR AUTOIMMUNE DISEASE DETECTION TO DRIVE MARKET

10.5

NEUROLOGICAL DISORDERS

10.5.1

WIDE USE OF BIOMARKERS IN DIAGNOSIS AND PRECISION MEDICINE OF NEUROLOGICAL DISORDERS TO SUPPORT GROWTH

10.6

CARDIOVASCULAR DISORDERS

10.6.1

GROWING PREVALENCE OF CVD TO INCREASE DEMAND FOR CARDIAC BIOMARKERS

10.7

OTHER DISEASE INDICATIONS

BIOMARKERS MARKET, BY APPLICATION

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 38 Data Tables

251

11.1

INTRODUCTION

11.2

CLINICAL DIAGNOSTICS

11.2.1

GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND

11.3

DRUG DISCOVERY & DEVELOPMENT

11.3.1

INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH

11.4

PERSONALIZED MEDICINE

11.4.1

GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND

11.5

CLINICAL RESEARCH

11.5.1

GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET

11.6

OTHER APPLICATIONS

BIOMARKERS MARKET, BY END USER

Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 30 Data Tables

272

12.1

INTRODUCTION

12.2

PHARMACEUTICAL & BIOTECHNOLOGIES COMPANIES

12.2.1

GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH

12.3

HOSPITALS & DIAGNOSTIC LABORATORIES

12.3.1

VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH

12.4

ACADEMIC & RESEARCH INSTITUTES

12.4.1

INCREASING FUNDING ACTIVITIES TO DRIVE MARKET

12.5

OTHER END USERS

BIOMARKERS MARKET, BY REGION

Comprehensive coverage of 7 Regions with country-level deep-dive of 19 Countries | 293 Data Tables.

289

13.1

INTRODUCTION

13.2

NORTH AMERICA

13.2.1

MACROECONOMIC OUTLOOK OF NORTH AMERICA

13.2.2

13.2.2.1

RISING FOCUS ON BIOPHARMA RESEARCH TO SUPPORT GROWTH

13.2.3

CANADA

13.2.3.1

INCREASING INCIDENCE OF CANCER TO DRIVE BIOMARKERS MARKET GROWTH

13.3

EUROPE

13.3.1

MACROECONOMIC OUTLOOK FOR EUROPE

13.3.2

GERMANY

13.3.2.1

GROWTH IN BIOPHARMACEUTICAL R&D ACTIVITIES TO PROPEL GROWTH

13.3.3

13.3.3.1

GOVERNMENT FUNDING AND STRATEGIC COLLABORATIONS WITH BIOTECH FIRMS TO BOOST ADOPTION OF BIOMARKERS

13.3.4

FRANCE

13.3.4.1

INCREASING GOVERNMENT INVESTMENT FOR PROTEOMICS & GENOMICS RESEARCH TO DRIVE GROWTH

13.3.5

ITALY

13.3.5.1

INCREASING DEVELOPMENTS IN LIFE SCIENCE RESEARCH TO FUEL GROWTH

13.3.6

SPAIN

13.3.6.1

R&D INITIATIVES FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH

13.3.7

REST OF EUROPE

13.4

ASIA PACIFIC

13.4.1

MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

13.4.2

CHINA

13.4.2.1

RISING INCIDENCE OF CVD TO PROPEL MARKET

13.4.3

JAPAN

13.4.3.1

STRONG REGULATORY GUIDELINES FOR DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH

13.4.4

INDIA

13.4.4.1

FAVORABLE SCENARIO FOR FDI AND INCREASING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET

13.4.5

SOUTH KOREA

13.4.5.1

INCREASING INNOVATIONS IN NGS TECHNOLOGIES TO SUPPORT MARKET GROWTH

13.4.6

AUSTRALIA

13.4.6.1

INCREASING DEMAND FOR DIAGNOSTIC SOLUTIONS TO PROPEL MARKET

13.4.7

REST OF ASIA PACIFIC

13.5

LATIN AMERICA

13.5.1

MACROECONOMIC OUTLOOK FOR LATIN AMERICA

13.5.2

BRAZIL

13.5.2.1

INCREASED GOVERNMENT INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET

13.5.3

MEXICO

13.5.3.1

RISING DEMAND FOR CHRONIC DISEASE TREATMENT TO SUPPORT MARKET GROWTH

13.5.4

REST OF LATIN AMERICA

13.6

MIDDLE EAST

13.6.1

MACROECONOMIC OUTLOOK FOR MIDDLE EAST

13.6.2

GCC COUNTRIES

13.6.3

SAUDI ARABIA

13.6.3.1

GROWING HEALTHCARE EXPENDITURE TO BOOST MARKET GROWTH

13.6.4

UAE

13.6.4.1

INCREASING COLLABORATIVE EFFORTS FOR PHARMACEUTICAL R&D TO DRIVE GROWTH

13.6.5

REST OF GCC COUNTRIES

13.6.5.1

OTHER GCC COUNTRIES INCLUDE BAHRAIN, KUWAIT, OMAN, AND QATAR.

13.6.6

REST OF MIDDLE EAST

13.6.6.1

THE REST OF THE MIDDLE EAST INCLUDES EGYPT, TURKEY, IRAN, AND IRAQ.

13.7

AFRICA

13.7.1

INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET

13.7.2

MACROECONOMIC OUTLOOK FOR AFRICA

COMPETITIVE LANDSCAPE

Discover top strategies and market positions of leading biomarker companies and emerging startups.

432

14.1

INTRODUCTION

14.2

KEY PLAYER STRATEGIES/RIGHT TO WIN

14.2.1

OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET

14.3

REVENUE ANALYSIS, 2022–2024

14.4

MARKET SHARE ANALYSIS, 2024

14.5

COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

14.5.1

STARS

14.5.2

EMERGING LEADERS

14.5.3

PERVASIVE PLAYERS

14.5.4

PARTICIPANTS

14.5.5

COMPANY FOOTPRINT: KEY PLAYERS, 2024

14.5.5.1

COMPANY FOOTPRINT

14.5.5.2

REGION FOOTPRINT

14.5.5.3

OFFERING FOOTPRINT

14.5.5.4

TECHNOLOGY FOOTPRINT

14.5.5.5

APPLICATION FOOTPRINT

14.6

COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024

14.6.1

PROGRESSIVE COMPANIES

14.6.2

RESPONSIVE COMPANIES

14.6.3

DYNAMIC COMPANIES

14.6.4

STARTING BLOCKS

14.6.5

COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

14.6.5.1

DETAILED LIST OF KEY STARTUPS/SMES

14.6.5.2

COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

14.7

COMPANY VALUATION & FINANCIAL METRICS

14.7.1

VALUATION OF KEY PLAYERS

14.7.2

FINANCIAL METRICS OF KEY PLAYERS

14.8

BRAND/PRODUCT COMPARATIVE ANALYSIS

14.8.1

BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS

14.9

COMPETITIVE SCENARIO

14.9.1

PRODUCT LAUNCHES & APPROVALS

14.9.2

DEALS

14.9.3

EXPANSIONS

COMPANY PROFILES

In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)

462

15.1

KEY PLAYERS

15.1.1

THERMO FISHER SCIENTIFIC INC.

15.1.1.1

BUSINESS OVERVIEW

15.1.1.2

PRODUCTS & SERVICES OFFERED

15.1.1.3

RECENT DEVELOPMENTS

15.1.1.4

MNM VIEW

15.1.2

MERCK KGAA

15.1.3

F. HOFFMANN-LA ROCHE LTD.

15.1.4

QIAGEN

15.1.5

ABBOTT

15.1.6

AGILENT TECHNOLOGIES, INC.

15.1.7

REVVITY INC.

15.1.8

CHARLES RIVER LABORATORIES

15.1.9

BIO-RAD LABORATORIES, INC.

15.1.10

EUROFINS SCIENTIFIC

15.1.11

BIOMÉRIEUX

15.1.12

ILLUMINA, INC.

15.1.13

JSR CORPORATION

15.1.14

GUARDANT HEALTH

15.1.15

LABCORP

15.1.16

QUANTERIX

15.1.17

MESO SCALE DIAGNOSTICS, LLC

15.2

OTHER PLAYERS

15.2.1

CELERION

15.2.2

STANDARD BIOTOOLS

15.2.3

SEBIA

15.2.4

BIOAGILYTIX LABS

15.2.5

STRESSMARQ BIOSCIENCES INC.

15.2.6

NORTHEAST BIOANALYTICAL LABORATORIES LLC

15.2.7

SIGNOSIS

15.2.8

SERIMMUNE

15.2.9

THERAINDX LIFESCIENCES PVT. LTD.

15.2.10

SYNEXA LIFE SCIENCES BV

15.2.11

DIATECH PHARMACOGENETICS

15.2.12

SINGULEX, INC.

15.2.13

R-BIOPHARM AG

APPENDIX

549

16.1

DISCUSSION GUIDE

16.2

KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

16.3

CUSTOMIZATION OPTIONS

16.4

RELATED REPORTS

16.5

AUTHOR DETAILS

LIST OF TABLES

TABLE 1

BIOMARKERS MARKET: IMPACT ANALYSIS

TABLE 2

CANCER INCIDENCE, BY REGION (2040)

TABLE 3

BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, 2022−2024

TABLE 4

TIMEFRAME FOR BIOMARKER DEVELOPMENT

TABLE 5

NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 6

EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 7

ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 8

REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 9

INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2022–2024 (USD)

TABLE 10

INDICATIVE SELLING PRICE TREND OF BIOMARKER CONSUMABLES, BY REGION, 2024 (USD)

TABLE 11

NUMBER OF PATENTS FILED IN BIOMARKERS MARKET, 2014–2025

TABLE 12

DETAILED ANALYSIS OF KEY PATENTS IN BIOMARKERS MARKET, 2024–2025

TABLE 13

BIOMARKERS MARKET: ECOSYSTEM

TABLE 14

BIOMARKERS MARKET: LIST OF CONFERENCES & EVENTS, 2025–2026

TABLE 15

BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS

TABLE 16

INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKER-BASED OFFERINGS

TABLE 17

BUYING CRITERIA FOR BIOMARKER PRODUCTS, BY END USER

TABLE 18

CANCER BIOMARKER FUNDING BY VARIOUS INSTITUTES/CENTERS IN US, 2021–2024

TABLE 19

IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2020–2024 (USD THOUSAND)

TABLE 20

EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2020–2024 (USD THOUSAND)

TABLE 21

TABLE 1: US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 22

BIOMARKER PRODUCT-RELATED TARIFF REVISIONS

TABLE 23

IMPACT ON END-USE APPLICATIONS OF BIOMARKER PRODUCTS

TABLE 24

BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 25

BIOMARKER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 26

NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 27

EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 28

ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 29

LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 30

MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 31

GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 32

BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 33

BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY REGION, 2023–2030 (USD MILLION)

TABLE 34

NORTH AMERICA: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 35

EUROPE: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 36

ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 37

LATIN AMERICA: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 38

MIDDLE EAST: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY REGION, 2023–2030 (USD MILLION)

TABLE 39

GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET FOR ASSAY KITS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 40

BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY REGION, 2023–2030 (USD MILLION)

TABLE 41

NORTH AMERICA: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 42

EUROPE: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 43

ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 44

LATIN AMERICA: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 45

MIDDLE EAST: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY REGION, 2023–2030 (USD MILLION)

TABLE 46

GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET FOR REAGENTS & CHEMICALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 47

OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 48

NORTH AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 49

EUROPE: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 50

ASIA PACIFIC: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 51

LATIN AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 52

MIDDLE EAST: OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 53

GCC COUNTRIES: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 54

BIOMARKER SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 55

NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 56

EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 57

ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 58

LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 59

MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 60

GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 61

BIOMARKER SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 62

NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 63

EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 64

ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 65

LATIN AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 66

MIDDLE EAST: BIOMARKER SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 67

GCC COUNTRIES: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 68

BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 69

SAFETY BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 70

NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 71

EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 72

ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 73

LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 74

MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 75

GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 76

EFFICACY BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 77

NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 78

EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 79

ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 80

LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 81

MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 82

GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 83

EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 84

PREDICTIVE BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 85

NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 86

EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 87

ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 88

LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 89

MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 90

GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 91

SURROGATE BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 92

NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 93

EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 94

ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 95

LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 96

MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 97

GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 98

PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 99

NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 100

EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 101

ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 102

LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 103

MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 104

GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 105

PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 106

NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 107

EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 108

ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 109

LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 110

MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 111

GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 112

VALIDATION BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 113

NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 114

EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 115

ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 116

LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 117

MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 118

GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 119

BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 120

BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 121

NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 122

EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 123

ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 124

LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 125

MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 126

GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 127

BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 128

NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 129

EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 130

ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 131

LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 132

MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 133

GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 134

BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 135

NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 136

EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 137

ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 138

LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 139

MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 140

GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 141

BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2023–2030 (USD MILLION)

TABLE 142

NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 143

EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 144

ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 145

LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 146

MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2023–2030 (USD MILLION)

TABLE 147

GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 148

BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 149

BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2023–2030 (USD MILLION)

TABLE 150

NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 151

EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 152

ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 153

LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 154

MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2023–2030 (USD MILLION)

TABLE 155

GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 156

BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 157

BIOMARKERS MARKET FOR ELISA, BY REGION, 2023–2030 (USD MILLION)

TABLE 158

NORTH AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 159

EUROPE: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 160

ASIA PACIFIC: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 161

LATIN AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 162

MIDDLE EAST: BIOMARKERS MARKET FOR ELISA, BY REGION, 2023–2030 (USD MILLION)

TABLE 163

GCC COUNTRIES: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 164

BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)

TABLE 165

NORTH AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 166

EUROPE: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 167

ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 168

LATIN AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 169

MIDDLE EAST: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2023–2030 (USD MILLION)

TABLE 170

GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 171

BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2023–2030 (USD MILLION)

TABLE 172

NORTH AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 173

EUROPE: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 174

ASIA PACIFIC: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 175

LATIN AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 176

MIDDLE EAST: BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2023–2030 (USD MILLION)

TABLE 177

GCC COUNTRIES: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 178

BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)

TABLE 179

NORTH AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 180

EUROPE: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 181

ASIA PACIFIC: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 182

LATIN AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 183

MIDDLE EAST: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)

TABLE 184

GCC COUNTRIES: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, 2023–2030 (USD MILLION)

TABLE 185

BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)

TABLE 186

NORTH AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 187

EUROPE: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 188

ASIA PACIFIC: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 189

LATIN AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 190

MIDDLE EAST: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)

TABLE 191

GCC COUNTRIES: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 192

BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)

TABLE 193

NORTH AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 194

EUROPE: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 195

ASIA PACIFIC: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 196

LATIN AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 197

MIDDLE EAST: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)

TABLE 198

GCC COUNTRIES: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 199

BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION)

TABLE 200

NORTH AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 201

EUROPE: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 202

ASIA PACIFIC: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 203

LATIN AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 204

MIDDLE EAST: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION)

TABLE 205

GCC COUNTRIES: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 206

BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 207

NORTH AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 208

EUROPE: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 209

ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 210

LATIN AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 211

MIDDLE EAST: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 212

GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 213

BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 214

LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE

TABLE 215

BIOMARKERS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION)

TABLE 216

NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 217

EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 218

ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 219

LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 220

MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION)

TABLE 221

GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 222

BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 223

NORTH AMERICA: INFECTIOUS DISEASES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 224

EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 225

ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 226

LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 227

MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 228

GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 229

BIOMARKERS FOR IMMUNOLOGICAL DISORDERS

TABLE 230

BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 231

NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 232

EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 233

ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 234

LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 235

MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 236

GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 237

BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 238

NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 239

EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 240

ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 241

LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 242

MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 243

GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 244

BIOMARKERS FOR CARDIOVASCULAR DISORDERS

TABLE 245

BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 246

NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 247

EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 248

ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 249

LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 250

MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 251

GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 252

BIOMARKERS FOR RENAL DISORDERS

TABLE 253

BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 254

NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 255

EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 256

ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 257

LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 258

MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 259

GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 260

BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 261

BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 262

NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 263

EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 264

ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 265

LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 266

MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)

TABLE 267

GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 268

BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)

TABLE 269

NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 270

EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 271

ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 272

LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 273

MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION)

TABLE 274

GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 275

LIST OF KEY PERSONALIZED MEDICINE AND RELEVANT BIOMARKERS

TABLE 276

BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION)

TABLE 277

NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 278

EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 279

ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 280

LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 281

MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2023–2030 (USD MILLION)

TABLE 282

GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 283

NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION

TABLE 284

BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION)

TABLE 285

NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 286

EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 287

ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 288

LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 289

MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION)

TABLE 290

GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 291

BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 292

NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 293

EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 294

ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 295

LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 296

MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 297

GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 298

BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 299

PHARMA & BIOTECH SECTOR: RECENT DEVELOPMENTS

TABLE 300

BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 301

NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 302

EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 303

ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 304

LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 305

MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 306

GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 307

BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 308

NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 309

EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 310

ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 311

LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 312

MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 313

GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 314

BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 315

NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 316

EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 317

ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 318

LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 319

MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 320

GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 321

BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 322

NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 323

EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 324

ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 325

LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 326

MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 327

GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 328

BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 329

NORTH AMERICA: KEY MACROINDICATORS

TABLE 330

NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 331

NORTH AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 332

NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 333

NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 334

NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 335

NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 336

NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 337

NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 338

NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 339

NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 340

NORTH AMERICA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 341

US: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 342

US: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 343

US: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 344

US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 345

US: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 346

US: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 347

US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 348

US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 349

US: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 350

US: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 351

CANADA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 352

CANADA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 353

CANADA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 354

CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 355

CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 356

CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 357

CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 358

CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 359

CANADA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 360

CANADA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 361

EUROPE: KEY MACROINDICATORS

TABLE 362

EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 363

EUROPE: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 364

EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 365

EUROPE: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 366

EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 367

EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 368

EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 369

EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 370

EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 371

EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 372

EUROPE: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 373

GERMANY: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 374

GERMANY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 375

GERMANY: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 376

GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 377

GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 378

GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 379

GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 380

GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 381

GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 382

GERMANY: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 383

UK: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 384

UK: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 385

UK: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 386

UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 387

UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 388

UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 389

UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 390

UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 391

UK: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 392

UK: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 393

FRANCE: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 394

FRANCE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 395

FRANCE: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 396

FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 397

FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 398

FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 399

FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 400

FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 401

FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 402

FRANCE: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 403

ITALY: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 404

ITALY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 405

ITALY: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 406

ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 407

ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 408

ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 409

ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 410

ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 411

ITALY: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 412

ITALY: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 413

SPAIN: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 414

SPAIN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 415

SPAIN: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 416

SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 417

SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 418

SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 419

SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 420

SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 421

SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 422

SPAIN: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 423

REST OF EUROPE: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 424

REST OF EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 425

REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 426

REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 427

REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 428

REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 429

REST OF EUROPE: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 430

REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 431

REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 432

REST OF EUROPE: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 433

ASIA PACIFIC: KEY MACROINDICATORS

TABLE 434

ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 435

ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 436

ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 437

ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 438

ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 439

ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 440

ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 441

ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 442

ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 443

ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 444

ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 445

CHINA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 446

CHINA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 447

CHINA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 448

CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 449

CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 450

CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 451

CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 452

CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 453

CHINA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 454

CHINA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 455

JAPAN: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 456

JAPAN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 457

JAPAN: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 458

JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 459

JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 460

JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 461

JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 462

JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 463

JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 464

JAPAN: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 465

INDIA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 466

INDIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 467

INDIA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 468

INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 469

INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 470

INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 471

INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 472

INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 473

INDIA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 474

INDIA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 475

SOUTH KOREA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 476

SOUTH KOREA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 477

SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 478

SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 479

SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 480

SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 481

SOUTH KOREA: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 482

SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 483

SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 484

SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 485

AUSTRALIA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 486

AUSTRALIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 487

AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 488

AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 489

AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 490

AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 491

AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 492

AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 493

AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 494

AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 495

REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 496

REST OF ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 497

REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 498

REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 499

REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 500

REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 501

REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 502

REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 503

REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 504

REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 505

LATIN AMERICA: KEY MACROINDICATORS

TABLE 506

LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 507

LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 508

LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 509

LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 510

LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 511

LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 512

LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 513

LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 514

LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 515

LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 516

LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 517

BRAZIL: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 518

BRAZIL: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 519

BRAZIL: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 520

BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 521

BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 522

BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 523

BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 524

BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 525

BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 526

BRAZIL: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 527

MEXICO: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 528

MEXICO: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 529

MEXICO: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 530

MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 531

MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 532

MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 533

MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 534

MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 535

MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 536

MEXICO: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 537

REST OF LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 538

REST OF LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 539

REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 540

REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 541

REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 542

REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 543

REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 544

REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 545

REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 546

REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 547

MIDDLE EAST: KEY MACROINDICATORS

TABLE 548

MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 549

MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 550

MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 551

MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 552

MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 553

MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 554

MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 555

MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 556

MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 557

MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 558

MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 559

GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 560

GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 561

GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 562

GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 563

GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 564

GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 565

GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 566

GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 567

GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 568

GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 569

GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 570

SAUDI ARABIA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 571

SAUDI ARABIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 572

SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 573

SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 574

SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 575

SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 576

SAUDI ARABIA: BIOMARKERS MARKET BY IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 577

SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 578

SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 579

SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 580

UAE: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 581

UAE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 582

UAE: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 583

UAE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 584

UAE: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 585

UAE: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 586

UAE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 587

UAE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 588

UAE: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 589

UAE: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 590

REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 591

REST OF GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 592

REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 593

REST OF GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 594

REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 595

REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 596

REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 597

REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 598

REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 599

REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 600

REST OF MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 601

REST OF MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 602

REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 603

REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 604

REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 605

REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 606

REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 607

REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 608

REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 609

REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 610

AFRICA: KEY MACROINDICATORS

TABLE 611

AFRICA: BIOMARKERS MARKET, BY OFFERING, 2023–2030 (USD MILLION)

TABLE 612

AFRICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 613

AFRICA: BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 614

AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 615

AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2023–2030 (USD MILLION)

TABLE 616

AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 617

AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 618

AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2023–2030 (USD MILLION)

TABLE 619

AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 620

AFRICA: BIOMARKERS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 621

OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET

TABLE 622

BIOMARKERS MARKET: DEGREE OF COMPETITION

TABLE 623

BIOMARKERS MARKET: REGION FOOTPRINT

TABLE 624

BIOMARKERS MARKET: OFFERING FOOTPRINT

TABLE 625

BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT

TABLE 626

BIOMARKERS MARKET: APPLICATION FOOTPRINT

TABLE 627

BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS

TABLE 628

BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES PLAYERS

TABLE 629

BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025

TABLE 630

BIOMARKERS MARKET: DEALS, JANUARY 2022–MAY 2025

TABLE 631

BIOMARKERS MARKET: EXPANSIONS, JANUARY 2022–MAY 2025

TABLE 632

THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW

TABLE 633

THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED

TABLE 634

THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025

TABLE 635

THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–APRIL 2025

TABLE 636

THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–APRIL 2025

TABLE 637

MERCK KGAA: BUSINESS OVERVIEW

TABLE 638

MERCK KGAA OFFERINGS: PRODUCTS & SERVICES OFFERED

TABLE 639

MERCK KGAA: DEALS, JANUARY 2022–APRIL 2025

TABLE 640

MERCK KGAA: EXPANSIONS, JANUARY 2022–APRIL 2025

TABLE 641

F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW

TABLE 642

F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED

TABLE 643

F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025

TABLE 644

F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–APRIL 2025

TABLE 645

QIAGEN: BUSINESS OVERVIEW

TABLE 646

QIAGEN: PRODUCTS & SERVICES OFFERED

TABLE 647

QIAGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025

TABLE 648

QIAGEN: DEALS, JANUARY 2022–APRIL 2025

TABLE 649

QIAGEN: EXPANSIONS, JANUARY 2022–APRIL 2025

TABLE 650

ABBOTT: BUSINESS OVERVIEW

TABLE 651

ABBOTT: PRODUCTS & SERVICES OFFERED

TABLE 652

ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022—APRIL 2025

TABLE 653

ABBOTT: DEALS, JANUARY 2022—APRIL 2025

TABLE 654

AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW

TABLE 655

AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED

TABLE 656

AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022—APRIL 2025

TABLE 657

AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022—APRIL 2025

TABLE 658

REVVITY INC.: BUSINESS OVERVIEW

TABLE 659

REVVITY INC.: PRODUCTS & SERVICES OFFERED

TABLE 660

CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW

TABLE 661

CHARLES RIVER LABORATORIES: PRODUCTS & SERVICES OFFERED

TABLE 662

CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022—APRIL 2025

TABLE 663

BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW

TABLE 664

BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED

TABLE 665

BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022—APRIL 2025

TABLE 666

BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022—APRIL 2025

TABLE 667

EUROFINS SCIENTIFIC: BUSINESS OVERVIEW

TABLE 668

EUROFINS SCIENTIFIC: PRODUCTS & SERVICES OFFERED

TABLE 669

EUROFINS SCIENTIFIC: DEALS, JANUARY 2022—APRIL 2025

TABLE 670

BIOMÉRIEUX: BUSINESS OVERVIEW

TABLE 671

BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED

TABLE 672

BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025

TABLE 673

BIOMÉRIEUX: DEALS, JANUARY 2022—APRIL 2025

TABLE 674

ILLUMINA, INC.: BUSINESS OVERVIEW

TABLE 675

ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED

TABLE 676

ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025

TABLE 677

ILLUMINA, INC.: DEALS, JANUARY 2022—APRIL 2025

TABLE 678

JSR CORPORATION: BUSINESS OVERVIEW

TABLE 679

JSR CORPORATION: PRODUCTS & SERVICES OFFERED

TABLE 680

JSR CORPORATION: DEALS, JANUARY 2022—APRIL 2025

TABLE 681

GUARDANT HEALTH: BUSINESS OVERVIEW

TABLE 682

GUARDANT HEALTH: PRODUCTS & SERVICES OFFERED

TABLE 683

GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–APRIL 2025

TABLE 684

GUARDANT HEALTH: DEALS, JANUARY 2022—APRIL 2025

TABLE 685

LABCORP: BUSINESS OVERVIEW

TABLE 686

LABCORP: PRODUCTS & SERVICES OFFERED

TABLE 687

LABCORP: PRODUCT LAUNCHES, JANUARY 2022—APRIL 2025

TABLE 688

QUANTERIX: BUSINESS OVERVIEW

TABLE 689

QUANTERIX: PRODUCTS & SERVICES OFFERED

TABLE 690

QUANTERIX: PRODUCT LAUNCHES, JANUARY 2022—APRIL 2025

TABLE 691

QUANTERIX: DEALS, JANUARY 2022—APRIL 2025

TABLE 692

MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW

TABLE 693

MESO SCALE DIAGNOSTICS, LLC: PRODUCTS & SERVICES OFFERED

TABLE 694

CELERION: COMPANY OVERVIEW

TABLE 695

STANDARD BIOTOOLS: COMPANY OVERVIEW

TABLE 696

SEBIA: COMPANY OVERVIEW

TABLE 697

BIOAGILYTIX LABS: COMPANY OVERVIEW

TABLE 698

STRESSMARQ BIOSCIENCES INC.: COMPANY OVERVIEW

TABLE 699

NORTHEAST BIOANALYTICAL LABORATORIES LLC: BUSINESS OVERVIEW

TABLE 700

SIGNOSIS: BUSINESS OVERVIEW

TABLE 701

SERIMMUNE: BUSINESS OVERVIEW

TABLE 702

THERAINDX LIFESCIENCES PVT. LTD.: BUSINESS OVERVIEW

TABLE 703

SYNEXA LIFE SCIENCES BV: BUSINESS OVERVIEW

TABLE 704

DIATECH PHARMACOGENETICS: BUSINESS OVERVIEW

TABLE 705

SINGULEX, INC.: BUSINESS OVERVIEW

TABLE 706

R-BIOPHARM AG: BUSINESS OVERVIEW

LIST OF FIGURES

FIGURE 1

RESEARCH DESIGN

FIGURE 2

BIOMARKERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS

FIGURE 3

BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024

FIGURE 4

MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024

FIGURE 5

ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2024)

FIGURE 6

MARKET SIZE VALIDATION FROM PRIMARY SOURCES

FIGURE 7

MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

FIGURE 8

BIOMARKERS MARKET (SUPPLY SIDE): CAGR PROJECTIONS

FIGURE 9

BIOMARKERS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS

FIGURE 10

DATA TRIANGULATION METHODOLOGY

FIGURE 11

BIOMARKERS MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)

FIGURE 12

BIOMARKERS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 13

BIOMARKERS MARKET, BY RESEARCH AREA, 2025 VS. 2030 (USD MILLION)

FIGURE 14

BIOMARKERS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)

FIGURE 15

BIOMARKERS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 16

GEOGRAPHIC ANALYSIS: BIOMARKERS MARKET

FIGURE 17

GROWING PIPELINE OF PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH

FIGURE 18

CONSUMABLES ACCOUNTED FOR LARGEST SHARE OF BIOMARKERS MARKET IN ASIA PACIFIC IN 2024

FIGURE 19

PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD

FIGURE 20

CHINA IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL BIOMARKERS MARKET DURING FORECAST PERIOD

FIGURE 21

BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 22

TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

FIGURE 23

BIOMARKERS MARKET: VALUE CHAIN ANALYSIS

FIGURE 24

AVERAGE SELLING PRICE OF ASSAY KITS, BY KEY PLAYER, 2022–2024 (USD)

FIGURE 25

PATENT ANALYSIS OF BIOMARKERS MARKET, JANUARY 2014–MAY 2025

FIGURE 26

BIOMARKERS MARKET: ECOSYSTEM ANALYSIS

FIGURE 27

BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS

FIGURE 28

INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOMARKER-BASED OFFERINGS

FIGURE 29

KEY BUYING CRITERIA FOR END USERS

FIGURE 30

IMPACT OF AI ON BIOMARKER ECOSYSTEM

FIGURE 31

NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT

FIGURE 32

ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT

FIGURE 33

REVENUE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2022–2024 (USD MILLION)

FIGURE 34

MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2024

FIGURE 35

BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 36

BIOMARKERS MARKET: COMPANY FOOTPRINT

FIGURE 37

BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 38

EV/EBITDA OF KEY VENDORS

FIGURE 39

YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 40

BIOMARKER MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF BIOMARKER-BASED ASSAYS

FIGURE 41

THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)

FIGURE 42

MERCK KGAA: COMPANY SNAPSHOT (2024)

FIGURE 43

F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)

FIGURE 44

QIAGEN: COMPANY SNAPSHOT (2024)

FIGURE 45

ABBOTT: COMPANY SNAPSHOT (2024)

FIGURE 46

AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)

FIGURE 47

REVVITY INC.: COMPANY SNAPSHOT (2024)

FIGURE 48

CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)

FIGURE 49

BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)

FIGURE 50

EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)

FIGURE 51

BIOMÉRIEUX: COMPANY SNAPSHOT (2024)

FIGURE 52

ILLUMINA, INC.: COMPANY SNAPSHOT (2024)

FIGURE 53

JSR CORPORATION: COMPANY SNAPSHOT (2023)

FIGURE 54

GUARDANT HEALTH: COMPANY SNAPSHOT (2024)

FIGURE 55

LABCORP: COMPANY SNAPSHOT (2024)

FIGURE 56

QUANTERIX: COMPANY SNAPSHOT (2024)

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the biomarkers market. The secondary sources used for this study include American Society of Clinical Oncology (ASCO), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organization (CDSCO), Center for Disease Evaluation and Research (CDER), Centers for Disease Control and Prevention (CDC), Chinese Medical Journal, Clinicaltrials.gov.in, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), Organization for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), PubMed, World Bank, World Health Organization (WHO), Corporate and Regulatory Filings, Annual Reports, Sec Filings, Investor Presentations, and Financial Statements; Business Magazines & Research Journals; Press Releases, MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global biomarkers market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & and biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, across six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the biomarkers market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

The key players in the industry and market have been identified through extensive secondary research.
The revenues generated from the biomarkers market business of leading players have been determined through primary and secondary research.
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Market Definition

A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes. The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery and development, personalized medicine, and clinical research. It also studies the adoption of biomarkers across key research areas, such as oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type of biomarkers, including safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarker landscape.

Stakeholders

Academic & Research Institutes
Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
Contract Research Organizations (CROs)
Biomarkers Service & Software Providers
Diagnostics Companies
Market Research and Consulting Firms
Pharmaceutical and Biotechnology Companies
Regulatory Agencies
Venture Capitalists
Forensics Labs
Government organizations
Private research firms
Contract development and manufacturing organizations (CDMOs)
Hospitals and Diagnostic Laboratories

Report Objectives

To define, describe, and forecast the global biomarkers market based on offering, type, research area, technology, disease indication, application, end user, and region
To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments in six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
To profile the key players in the global biomarkers market and comprehensively analyze their core competencies and market shares
To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
To benchmark players in the biomarkers market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share

Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

OVERVIEW

KEY TAKEAWAYS

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

MARKET DYNAMICS

Driver: Increasing use of biomarkers in drug discovery & development

Restraint: High capital investments and extensive timelines for biomarker development

Opportunity: Growing preference for personalized medicine and precision oncology

Challenge: Issues associated with quantification & validation of biomarkers

biomarkers-advanced-technologies-and-global-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

MARKET ECOSYSTEM

MARKET SEGMENTS

Biomarkers Market, By Offering

Biomarkers Market, By Type

Biomarkers Market, By Application

REGION

Asia Pacific to be fastest-growing region in global biomarkers market during forecast period

biomarkers-advanced-technologies-and-global-market: COMPANY EVALUATION MATRIX

KEY MARKET PLAYERS

MARKET SCOPE

WHAT IS IN IT FOR YOU: biomarkers-advanced-technologies-and-global-market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

RECENT DEVELOPMENTS

Table of Contents

Methodology

Secondary Research

Primary Research

Market Size Estimation

Bottom-up Approach

Top-down Approach

Data Triangulation

Market Definition

Stakeholders

Report Objectives

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Adjacent Markets

Personalize This Research

Let Us Help You

Growth opportunities and latent adjacency in Biomarkers Market

Patrick

Raymond

Jack